CSL (ASX:CSL) share price wobbles on plasma and vaccine update

The CSL Limited (ASX: CSL) share price has been in the spotlight in recent memory. We take a closer look as to what's lowering its shares.

| More on:
A man climbing stairs that go up and down in a chart style, indicating a moving share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has been in the spotlight in recent memory. This follows concerns over its plasma collections as well as its progress in producing the AstraZeneca COVID-19 vaccine.

At the time of writing, the global biotech's shares are trading for $264.64, down 1.3% for the day.

Plasma worries

COVID-19 has wreaked havoc on the global economy and virtually shut down foot traffic movement in the United States.

Unfortunately for CSL, this has affected its plasma collections as fewer people are donating blood to its collection centres. The company last provided an update in March advising that December 2020 plasma volumes were sitting around 80% of the December 2019 levels.

This has led CSL to approach the public for ideas on how it can maximise the yield and processing efficiency in human immunoglobulins.

CSL Behring's immunoglobulins are much needed for running its business operations. Derived from plasma, human immunoglobulins are a lifesaving therapy that prevent and fight rare and serious infections.

The company is offering $40,000 on the winning idea as well as two one-on-one mentoring sessions with CSL Behring.

COVID-19 vaccine update

Furthermore, CSL is striving to increase production of the AstraZeneca COVID-19 vaccine. So far, Australia has administered over 1.65 million vaccinations to the public, averaging around 60 thousand doses per day.

The Australian government has indicated that it's strongly considering bringing vaccine manufacturing capability to Australia within the next decade. This would protect Australians from present and future pandemics through local supply, avoiding political problems such as the European shipment block.

CSL has put its hand up for this proposal and is in current discussions with the Australian government. Although, it may take some time to set up such a facility and begin producing important vaccines.

Broker update

The latest broker update came from investment bank Macquarie yesterday, issuing a price target of $282.50 for CSL. While it may have cut its outlook by 1.9% from its original note, this represents an upside of almost 7%.

CSL share price review

Over the last 12 months, the CSL share price has faltered and is now trading at the same price as recorded in November 2019. The company's shares momentarily reached a high of $320.42 in late November 2020 before trending downwards and moving sideways since.

As one of the ASX market's largest companies in terms of market capitalisation, the CSL share price is valued at $120.2 billion. Furthermore, the company has more than 455 million shares on issue.

Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia owns shares of and has recommended Macquarie Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A woman with a broad smile on her face holds up ten fingers.
Share Market News

Here are the top 10 ASX 200 shares today

It was another happy day for most ASX 200 shares this Wednesday.

Read more »

Two CEOs shaking hands on a deal.
Mergers & Acquisitions

Wesfarmers share price rises amid latest acquisition news

The company has completed its latest acquisition.

Read more »

a woman holds a facebook like thumbs up sign high above her head. She has a very happy smile on her face.
Broker Notes

Why Bell Potter just upgraded this ASX 200 share to a buy rating

This share is exposed to structural growth tailwinds according to its analysts.

Read more »

A happy male investor turns around on his chair to look at a friend while a laptop runs on his desk showing share price movements
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

A male doctor wearing a white doctor's coat shrugs and holds his hands up to indicate the unimpressive CSL share price as a result of OOVID-19
Share Market News

Here's why you might have just bought Healius shares

Two of the most popular super funds just loaded up on this healthcare stock.

Read more »

A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer

These 2 ASX 200 shares just hit 52-week lows: I rate them as buys

These two stocks look too cheap to miss!

Read more »

A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
Share Fallers

Why Core Lithium, Deep Yellow, EML, and Wildcat shares are falling today

These ASX shares are having a tough time on Wednesday. But why?

Read more »

A young woman wearing overalls and a yellow t-shirt kicks one leg in the air showing excitement over the latest ASX 200 shares to hit 52-week highs
Share Gainers

Why Evolution, Fisher & Paykel, IDP Education, and Temple & Webster shares are jumping

These ASX shares are having a strong session on hump day. But why?

Read more »